quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·45d
PRRelease
Keros Therapeutics Inc. logo

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

KROS· Keros Therapeutics Inc.
Health Care
Original source

Companies

  • KROS
    Keros Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Oct 20UpdateWells Fargo$26.00
  • Jun 10UpdateBofA Securities$18.00
  • Jan 21UpdateCantor Fitzgerald-
  • Jan 17UpdateWedbush$15.00
  • Dec 16UpdateOppenheimer$63.00
  • Dec 16UpdateGuggenheim-

Related

  • SEC1d
    SEC Form DEFA14A filed by Keros Therapeutics Inc.
  • SEC1d
    SEC Form DEF 14A filed by Keros Therapeutics Inc.
  • INSIDER6d
    SEC Form 4 filed by Bienaime Jean Jacques
  • INSIDER17d
    SEC Form 4 filed by Seehra Jasbir
  • SEC23d
    SEC Form 144 filed by Keros Therapeutics Inc.
  • INSIDER27d
    Amendment: SEC Form 4 filed by Cho Esther
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Keros Therapeutics Inc.
  • INSIDER43d
    SEC Form 4 filed by Keros Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022